US biotech criticises govt panel recommendations on limiting gene patents
This article was originally published in RAJ Devices
A new report by a US government advisory panel recommending major changes to the current patent policy and licensing practices for genetic tests has been criticised by the biotech industry and other stakeholders who say it would “seriously hamper” public-private collaborations and the commercialisation of publicly funded research1-3.
You may also be interested in...
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.
A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.